The first patient has been dosed in Circio's TG01 triple combination study
· The first enrolled patient was dosed on 31 January in Washington, D.C., USA · In this phase 2 study, the TG01 mutant RAS cancer vaccine is being tested in combination with daratumumab (Janssen) and nivolumab (BMS) · This is the first time TG01 is tested in non-small cell lung cancer (NSCLC) Oslo, Norway, 1 February 2024 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA and immunotherapy medicines, today announces that the first patient has been dosed in the collaborative phase 2 trial sponsored by Georgetown University. In this study, mutant